PMID: 8598230Mar 1, 1996Paper

Analysis of CD34-positive cells in bone marrow from patients with myelodysplastic syndromes and acute myeloid leukemia and in normal individuals: a comparison between FACS analysis and immunohistochemistry

European Journal of Haematology
L Kanter-LewensohnA Ost

Abstract

In patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), expression of the hematopoietic stem cell marker CD34 has been associated with a poorer prognosis. CD34 is usually analyzed by flow cytometry (FC), but may also be analyzed using immunohistochemistry (IH). The present study was undertaken to compare these 2 methods. Bone marrow from 16 patients with MDS and 12 with AML and from 12 healthy young volunteers was studied. The expression of CD34 was analyzed with FC on fresh bone marrow cells and with IH on sections of paraffin-embedded bone marrow. The correlation between FC and IH was good both for patients with MDS (p<0.0001) and AML (p<0.01). However, in patients with a high number of CD34-positive cells, the FC method seemed to result in a higher percentage of positive cells compared to the IH method. In normal bone marrow, the ratio between the percentage of CD34-positive cells and the percentage of bone marrow blasts was approximately 0.8. In the whole group of MDS patients, this ratio was 1:1, while in patients with refractory anemia (RA) and ring sideroblastic anemia (RAS) it was 1.6. Patients with MDS differed significantly from patients with de novo AML, who showed a ratio of only 0.23 (p<0...Continue Reading

References

Feb 1, 1992·American Journal of Hematology·S A SullivanM E Jones
Jun 1, 1991·British Journal of Haematology·G Lambertenghi-DeliliersD Soligo
May 1, 1990·American Journal of Hematology·D GuyotatD Fiere
Mar 1, 1985·British Journal of Haematology·G J MuftiD Machin
Jun 1, 1994·British Journal of Haematology·J P MaciejewskiN S Young

❮ Previous
Next ❯

Citations

Jun 25, 1998·Leukemia & Lymphoma·K Sawada
Oct 30, 2009·American Journal of Clinical Pathology·Danielle M P CroninUma N Sundram
Apr 23, 2010·British Journal of Haematology·Maryam NikpourEva Hellström-Lindberg
Jul 13, 2018·Journal of Clinical and Experimental Hematopathology : JCEH·Hidekazu Kayano
Sep 2, 2003·American Journal of Hematology·Dongsheng XuHoward Ratech
Sep 19, 2006·British Journal of Haematology·Akos CzibereManuel Aivado
Dec 24, 2018·Seminars in Hematology·Aaron HodesRaul Braylan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.